Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rifampicin 600mg - tablet - 600 mg - active: rifampicin 600mg excipient: acacia calcium stearate carmellose sodium carnauba wax colloidal silicon dioxide colophony erythrosine ethanol gelatin hard paraffin kaolin lactose monohydrate magnesium carbonate magnesium stearate maize starch microcrystalline cellulose povidone purified talc purified water sodium laurilsulfate sucrose titanium dioxide white beeswax - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tuberculin purified protein derivative 27mg (freeze dried attentuated strain-mycobacterium bovis) - powder for injection - 27 mg - active: tuberculin purified protein derivative 27mg (freeze dried attentuated strain-mycobacterium bovis) excipient: monosodium glutamate dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride water for injection

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tuberculin purified protein derivative 81mg - powder for injection - 81 mg - active: tuberculin purified protein derivative 81mg excipient: monosodium glutamate

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - pneumococcal polysaccharide serotype 1 25ug; pneumococcal polysaccharide serotype 10a 25ug; pneumococcal polysaccharide serotype 11a 25ug; pneumococcal polysaccharide serotype 12f 25ug; pneumococcal polysaccharide serotype 14 25ug; pneumococcal polysaccharide serotype 15b 25ug; pneumococcal polysaccharide serotype 17f 25ug; pneumococcal polysaccharide serotype 18c 25ug; pneumococcal polysaccharide serotype 19a 25ug; pneumococcal polysaccharide serotype 19f 25ug; pneumococcal polysaccharide serotype 2 25ug; pneumococcal polysaccharide serotype 20 25ug; pneumococcal polysaccharide serotype 22f 25ug; pneumococcal polysaccharide serotype 23f 25ug; pneumococcal polysaccharide serotype 3 25ug; pneumococcal polysaccharide serotype 33f 25ug; pneumococcal polysaccharide serotype 4 25ug; pneumococcal polysaccharide serotype 5 25ug; pneumococcal polysaccharide serotype 6b 25ug; pneumococcal polysaccharide serotype 7f 25ug; pneumococcal polysaccharide serotype 8 25ug; pneumococcal polysaccharide serotype 9n 25ug; pneumococcal polysaccharide serotype 9v 25ug - suspension for injection - 25 mcg - active: pneumococcal polysaccharide serotype 1 25ug pneumococcal polysaccharide serotype 10a 25ug pneumococcal polysaccharide serotype 11a 25ug pneumococcal polysaccharide serotype 12f 25ug pneumococcal polysaccharide serotype 14 25ug pneumococcal polysaccharide serotype 15b 25ug pneumococcal polysaccharide serotype 17f 25ug pneumococcal polysaccharide serotype 18c 25ug pneumococcal polysaccharide serotype 19a 25ug pneumococcal polysaccharide serotype 19f 25ug pneumococcal polysaccharide serotype 2 25ug pneumococcal polysaccharide serotype 20 25ug pneumococcal polysaccharide serotype 22f 25ug pneumococcal polysaccharide serotype 23f 25ug pneumococcal polysaccharide serotype 3 25ug pneumococcal polysaccharide serotype 33f 25ug pneumococcal polysaccharide serotype 4 25ug pneumococcal polysaccharide serotype 5 25ug pneumococcal polysaccharide serotype 6b 25ug pneumococcal polysaccharide serotype 7f 25ug pneumococcal polysaccharide serotype 8 25ug pneumococcal polysaccharide serotype 9n 25ug pneumococcal polysaccharide serotype 9v 25ug excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenol sodium chloride water for injection - pneumo 23 is indicated for high risk subjects 2 years of age and above to prevent pneumococcal pneumonia and systemic pneumococcal infections caused by the serotypes included in the vaccine.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin aspart, quantity: 3.5 mg/ml - injection, solution - excipient ingredients: metacresol; phenol; polysorbate 20; sodium hydroxide; hydrochloric acid; water for injections; zinc chloride; sodium chloride - for the treatment of diabetes mellitus

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: saccharin; vanillin - treatment of hyperkalaemia.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -